Toronto– Side Effects Software Inc. (“Side Effects”), a leading provider of 3D animation software to the visual effects industry announces that it has secured a US$1.5 million venture loan from MMV Financial Inc.

Side Effects’ award winning software has been used by artists in Hollywood’s leading animation facilities for the last twenty years. Their flagship product Houdini is a complete, tightly integrated, scaleable and fully customizable 3D solution, backed by outstanding customer support and on-site production assistance.

"This financing enables Side Effects to aggressively pursue its growth strategy” said Kim Davidson, President and Chief Executive Officer of Side Effects. “We are looking forward to our new financial partnership with MMV.”

“We are excited to support an innovator in the 3D animation software marketplace” said Greg Dimmer, Senior Vice President, MMV Financial Inc. “We believe Side Effect’s award-winning Houdini technology, superior customer support and experienced management team will position the company well for continued growth in this dynamic market.”

About Side Effects Software

Established in 1987, Side Effects Software is a world leader in the development of advanced 3D animation and special effects software for use in film. Side Effects Software leads the field of procedural animation with its unique, award-winning, Houdini technology. Houdini is used by numerous digital content creation leaders including C.O.R.E., Digital Domain, Disney Feature Animation, Double Negative, Framestore-CFC, The Orphanage, Rhythm and Hues, and Sony Pictures Imageworks among others.

About MMV Financial Inc.

MMV Financial is a Toronto-based specialty finance company providing creative debt solutions to technology and life sciences companies across North America. MMV is backed by top U.S. and Canadian private equity firms and financial institutions including CCP Equity Partners, Caisse de dépôt et placement du Quebec, NewStar Financial Inc, and Wells Fargo Company. For more information visit www.mmvf.com.